Text this: Number and proportion of glaucoma patients continuing with their first-line therapy after 1, 3, and 5 years of follow-up in the FinHealth 2017 Survey sample representing the Finnish adult population aged 30 years or older according to their first-line glaucoma monotherapy drug class and type during the follow-up between 1995 and 2019.